How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

FDA Approves Luye’s Rykindo; EU Approves AstraZ...

FDA Approves Luye Pharma’s Rykindo for Schizophrenia Luye Pharma has received its first FDA approval for Rykindo, an injectable formulation of the antipsychotic risperidone administered every two w...

Jan 17, 2023

acute-ocular-pain-treatment-landscape
New Technologies Conquering Drug Delivery Obstacles in Acute Ocular Pain Treatment Landscape

Ocular pain is among the most common complaints in emergency clinics for medical attention. Most of the older population is affected by eye pain from post-ocular surgeries and debilitating eye conditions. Eye pain can be broadly classified as acute and chronic; eye pain exceeding 3 months is considered chronic. Mor...

Find More
behcets-syndrome-treatment-market
Off-label Therapies Dominating the Behcet’s Syndrome Treatment Market

Behcet’s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters. The HLA-B*5101 allele of HLA-...

Find More
eosinophilic-esophagitis-treatment-outlook
Is it the Dawn of Biologics in the Eosinophilic Esophagitis Treatment Landscape?

Eosinophilic Esophagitis (EoE) is a chronic inflammatory ailment that is immune-mediated. It is characterized by an increased number of eosinophils infiltrating the esophagus, thus, impacting one’s fundamental eating ability. It affects both adults and children and is caused by allergens; food antigens are consider...

Find More

More Views & Analysis

osteomyelitis-treatment-outlook
Osteomyelitis Treatment Market: Evaluating the New Line of Therapies in the Therapeutics Space

A bone marrow infection that tends to spread and frequently involves periosteal tissues and nearby cortical plates is known as osteomyelitis. It might be acute, subacute, or chronic. In most cases, acute osteomyelitis is hematogenous in origin, has a recent onset, and has a brief duration. It can also be brought on...

Find More

Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB
Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi

Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...

Find More

enhertu-for-cancer-treatment-and-management
ENHERTU’s Journey in Cancer Treatment and Management

ENHERTU is an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this ADC:  A topoisomerase inhibitor that is covalently linked to, Humanized anti-HER2 IgG1 monoclonal antibody (mAb) via, Tetrapeptide-based cleavable linker Rec...

Find More

emerging-therapies-for-pd-lid-treatment
Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management

Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...

Find More

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...

Find More

head and neck cancer market outlook
Awaited Approval for New Therapies for Head and Neck Cancer Treatment – A Race Against Time!

Head and neck cancer is a complex indication and is common among men and people over 50 and accounts for 3–5% of all cancers in the US. As per the assessment done by DelveInsight, there were approximately 158K incident cases of head and neck cancer in the 7MM in 2021. Among the EU5 countries, Germany had the highes...

Find More

Immune thrombocytopenic purpura (ITP) is a disorder that results in the immune system killing its pl.....

Find More

Hemophilia, a genetic bleeding disorder characterized by a clotting factor protein deficiency. Intak.....

Find More

Intra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....

Find More

Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....

Find More

The medical device (MedTech) industry has small and big companies operating in various segments such.....

Find More

A degenerative disease, Exocrine Pancreatic Insufficiency (EPI), is a consequence of insufficient pr.....

Find More